Now that their role in vaccine research is over, 117 chimpanzees in Japan
face an uncertain fate. The chimps were imported in 1975 for a hepatitis B
vaccine programme and are now in a holding facility run by the drug company
Sanwa Kagaku. The company says it can no longer afford the annual £1.5
million upkeep. There are only a few comparable chimp facilities in the world,
and all are government-subsidised. But the Japanese government is reluctant to
take responsibility for the chimps.
To continue reading, subscribe today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles


